Volume | 30,762 |
|
|||||
News | - | ||||||
Day High | 2.14 | Low High |
|||||
Day Low | 2.04 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Revelation Biosciences Inc | REVB | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.14 | 2.04 | 2.14 | 2.07 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
181 | 30,762 | $ 2.08 | $ 64,006 | - | 1.7801 - 39.30 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
13:44:36 | 200 | $ 2.11 | USD |
Revelation Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.1k | 209.91k | - | 0 | -120k | -0.57 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Revelation Biosciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical REVB Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.92 | 2.38 | 1.8801 | 2.17 | 62,656 | 0.19 | 9.90% |
1 Month | 2.60 | 2.96 | 1.7801 | 2.40 | 67,017 | -0.49 | -18.85% |
3 Months | 9.12 | 11.90 | 1.7801 | 3.65 | 322,459 | -7.01 | -76.86% |
6 Months | 18.915 | 25.26 | 1.7801 | 7.91 | 273,674 | -16.81 | -88.84% |
1 Year | 33.30 | 39.30 | 1.7801 | 16.62 | 221,723 | -31.19 | -93.66% |
3 Years | 8,799.00 | 10,237.50 | 1.7801 | 982.07 | 1,281,631 | -8,796.89 | -99.98% |
5 Years | 8,799.00 | 10,237.50 | 1.7801 | 982.07 | 1,281,631 | -8,796.89 | -99.98% |
Revelation Biosciences Description
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. |